The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Open accessAbstract
The TP53 tumor suppressor gene is frequently mutated in human cancers. An analysis of five data platforms in 10,225 patient samples from 32 cancers reported by The Cancer Genome Atlas (TCGA) enables comprehensive assessment of p53 pathway involvement in these cancers. More than 91% of TP53-mutant cancers exhibit second allele loss by mutation, chromosomal deletion, or copy-neutral loss of heterozygosity. TP53 mutations are associated with enhanced chromosomal instability, including increased amplification of oncogenes and deep deletion of tumor suppressor genes. Tumors with TP53 mutations differ from their non-mutated counterparts in RNA, miRNA, and protein expression patterns, with mutant TP53 tumors displaying enhanced expression of cell cycle progression genes and proteins. A mutant TP53 RNA expression signature shows significant correlation with reduced survival in 11 cancer types. Thus, TP53 mutation has profound effects on tumor cell genomic structure, expression, and clinical outlook.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TP53 is a negative regulator of cellular proliferation and is classed as a TSG, but it does not conform to this pattern; most mutational events in it are missense mutations dispersed across more than half of the protein (Fig. 1b,c) [6].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [6]
In the citing paper
“TP53 is the most frequently mutated gene in human malignancies, 50% of which carry alterations to it.”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [6]
In the citing paper
“TP53 is the most frequently mutated gene in human malignancies, 50% of which carry alterations to it.”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [6]
In the citing paper
“most mutational events in it are missense mutations dispersed across more than half of the protein (Fig. 1b,c) [6].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [6]
In the citing paper
“Situations involving different mutations in the two different alleles have also been observed, but they are very infrequent [6].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Self-citationWAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 1×
“Moreover, amplifications have been shown experimentally to be enhanced by mutant TP53 due in part to defective double-strand break repair and absence of p53-mediated apoptosis in response to proliferation of cells with double-strand DNA breaks (Hanel and Moll, 2012; Lengauer et al., 1998; Livingstone et al., 1992).”
BackgroundBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Genomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T. D. (1992) · Cell · doi:10.1016/0092-8674(92)90243-6 · Cited by 1,332
Nagy, Á., Lánczky, A., Menyhárt, O., & Győrffy, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-27521-y · Cited by 1,319
p53: A Frequent Target for Genetic Abnormalities in Lung Cancer
Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., & Minna, J. D. (1989) · Science · doi:10.1126/science.2554494 · Cited by 1,197
Pathway Commons, a web resource for biological pathway data
Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1039 · Cited by 1,101
Lujambio, A., & Lowe, S. W. (2012) · Nature · doi:10.1038/nature10888 · Cited by 1,084
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,063
Census and evaluation of p53 target genes
Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971
Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 874
DNA Replication Stress as a Hallmark of Cancer
Macheret, M., & Halazonetis, T. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040424 · Cited by 823
Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
Tetraploidy, aneuploidy and cancer
Ganem, N. J., Storchova, Z., & Pellman, D. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.02.011 · Cited by 668
Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM
Engeland, K. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.172 · Cited by 656
TP53 tumor suppressor gene: A model for investigating human mutagenesis
Fromentel, C. C. D., & Soussi, T. (1992) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870040102 · Cited by 574
Self-citationMutational processes shape the landscape of TP53 mutations in human cancer
Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556
p53 post-translational modification: deregulated in tumorigenesis
Dai, C., & Gu, W. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.002 · Cited by 523
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518
p53 and E2f: partners in life and death
Polager, S., & Ginsberg, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2718 · Cited by 498
Hereditary cancer: Two hits revisited
Knudson, A. G. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01366952 · Cited by 491
Liu, X.-Y., Gerges, N., Korshunov, A., Sabha, N., Khuong-Quang, D.-A., Fontebasso, A. M., Fleming, A., Hadjadj, D., Schwartzentruber, J., Majewski, J., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1031-3 · Cited by 428
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408
Self-citationClinical Outcomes and Correlates of TP53 Mutations and Cancer
Robles, A. I., & Harris, C. C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001016 · Cited by 394
Wildeman, M., van Ophuizen, E., den Dunnen, J. T., & Taschner, P. E. M. (2008) · Human Mutation · doi:10.1002/humu.20654 · Cited by 392
Crook, T., Wrede, D., Tidy, J. A., Vousden, K. H., Wrede, D., Tidy, J., Mason, W. P., & Evans, D. J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90662-m · Cited by 309
Soussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
Self-citationUse of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L. M., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301
Kotler, E., Shani, O., Goldfeld, G., Lotan-Pompan, M., Tarcic, O., Gershoni, A., Hopf, T. A., Marks, D. S., Oren, M., & Segal, E. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.012 · Cited by 285
Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K., Inagaki, A., Silber, J., Gorovets, D., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H., Chan, T. A., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 278
Mechanisms of p53 loss in human sarcomas.
Mulligan, L. M., Matlashewski, G. J., Scrable, H. J., & Cavenee, W. K. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.15.5863 · Cited by 269
The Role of MDM2 Amplification and Overexpression in Tumorigenesis
Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026336 · Cited by 246
TP53 loss creates therapeutic vulnerability in colorectal cancer
Liu, Y., Zhang, X., Han, C., Wan, G., Huang, X., Ivan, C., Jiang, D., Rodriguez-Aguayo, C., Lopez-Berestein, G., Rao, P. H., et al. (2015) · Nature · doi:10.1038/nature14418 · Cited by 241
Self-citationLu, X., Nguyen, T.-A., Moon, S.-H., Darlington, Y., Sommer, M., & Donehower, L. A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9127-x · Cited by 241
Self-citationLinks between mutant p53 and genomic instability
Hanel, W., & Moll, U. M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23400 · Cited by 216
Deciphering p53 signaling in tumor suppression
Mello, S. S., & Attardi, L. D. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.11.005 · Cited by 206
Loss of p53 and centrosome hyperamplification
Tarapore, P., & Fukasawa, K. (2002) · Oncogene · doi:10.1038/sj.onc.1205707 · Cited by 189
Pro-proliferative FoxM1 is a target of p53-mediated repression
Barsotti, A. M., & Prives, C. (2009) · Oncogene · doi:10.1038/onc.2009.282 · Cited by 166
Babur, Ö., Gönen, M., Aksoy, B. A., Schultz, N., Ciriello, G., Sander, C., & Demir, E. (2015) · Genome Biology · doi:10.1186/s13059-015-0612-6 · Cited by 166
The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data
Wilks, C., Cline, M., Weiler, E., Diehkans, M., Craft, B., Martin, C., Murphy, D., Pierce, H., Black, J., Nelson, D. R., et al. (2014) · Database · doi:10.1093/database/bau093 · Cited by 143
Soussi, T., Kato, S., Lévy, P., & Ishioka, C. (2004) · Human Mutation · doi:10.1002/humu.20114 · Cited by 139
Self-citationThe impact of p53 and p73 on aneuploidy and cancer
Tomasini, R., Mak, T. W., & Melino, G. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.03.003 · Cited by 127
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 123
Genomic instability and the role of p53 mutations in cancer cells
Smith, M. L., & Fornace, A. J. (1995) · Current Opinion in Oncology · doi:10.1097/00001622-199501000-00011 · Cited by 121
The Arf/p53 pathway in cancer and aging
Matheu, A., Maraver, A., & Serrano, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6851 · Cited by 105
Effects of TP53 mutational status on gene expression patterns across 10 human cancer types
Parikh, N., Hilsenbeck, S. G., Creighton, C. J., Dayaram, T., Shuck, R. L., Shinbrot, E., Liu, X., Gibbs, R. A., Wheeler, D. A., & Donehower, L. A. (2013) · The Journal of Pathology · doi:10.1002/path.4321 · Cited by 91
Self-citationJasek, M., Gondek, L. P., Bejanyan, N., Tiu, R. V., Huh, J. Y., Theil, K. S., O'Keefe, C., McDevitt, M. A., & Maciejewski, J. P. (2009) · Leukemia · doi:10.1038/leu.2009.189 · Cited by 83
Mutant TP53 Posttranslational Modifications: Challenges and Opportunities
Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W. (2014) · Human Mutation · doi:10.1002/humu.22506 · Cited by 69
ChiBE: interactive visualization and manipulation of BioPAX pathway models
Babur, Ö., Doğrusöz, U., Demir, E., & Sander, C. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp665 · Cited by 56
Mutational Analysis of the p53 Core Domain L1 Loop
Zupnick, A., & Prives, C. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603387200 · Cited by 52
Mechanisms of Mutant p53 Stabilization in Cancer
Frum, R. A., & Grossman, S. R. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_10 · Cited by 45
p53 suppresses structural chromosome instability after mitotic arrest in human cells
Dalton, W. B., Yu, B., & Yang, V. W. (2010) · Oncogene · doi:10.1038/onc.2009.477 · Cited by 43
Saeki, H., Kitao, H., Yoshinaga, K., Nakanoko, T., Kubo, N., Kakeji, Y., Morita, M., & Maehara, Y. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1996 · Cited by 42
Tainsky, M. A., Bischoff, F. Z., & Strong, L. C. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690210 · Cited by 39
Svobodová, K., Zemanová, Z., Lhotská, H., Novakova, M., Podskalska, L., Beličková, M., Březinová, J., Šárová, I., Izáková, S., Lizcová, L., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.01.009 · Cited by 32
Genetic instability in animal tumorigenesis models.
Donehower, L. (1997) · PubMed · Cited by 32
Self-citationRole of the p53 Family in Stabilizing the Genome and Preventing Polyploidization
Talos, F., & Moll, U. M. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6199-0_5 · Cited by 30
Stewart, D. R., Pemov, A., Loo, P. V., Beert, E., Brems, H., Sciot, R., Claes, K., Pak, E. D., Dutra, A., Lee, C. R., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21928 · Cited by 30
Integrating biological pathways and genomic profiles with ChiBE 2
Babur, Ö., Doğrusöz, U., Çakır, M., Aksoy, B. A., Schultz, N. D., Sander, C., & Demir, E. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-642 · Cited by 29
Soussi, T., Leroy, B., Devir, M., & Rosenberg, S. (2019) · Human Mutation · doi:10.1002/humu.23717 · Cited by 28
Self-citationKumar, Y., Yang, J., Hu, T., Chen, L., Xu, Z., Xu, L., Hu, X.-X., Tang, G., Wang, J.-M., Li, Y., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0104-2 · Cited by 25
Pattern search in BioPAX models
Babur, Ö., Aksoy, B. A., Rodchenkov, I. V., Sümer, S. O., Sander, C., & Demir, E. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt539 · Cited by 22
Soussi, T., & Kroemer, G. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.07.001 · Cited by 8
Self-citation
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
New Horizons in the Treatment of Osteosarcoma
Meltzer, P. S., & Helman, L. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2103423 · Cited by 672
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
Mutant p53 suppresses innate immune signaling to promote tumorigenesis
Ghosh, M., Saha, S., Bettke, J., Nagar, R., Parrales, A., Iwakuma, T., van der Velden, A. W. M., & Martinez, L. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.003 · Cited by 348
Metadata
- Authors
- Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O., Hsu, T.-K., Lichtarge, O., Weinstein, J. N., Akbani, R., & Wheeler, D. A.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 28
- Issue
- 5
- Pages
- 1370-1384.e5
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2964649258
- Cited by
- 710
- References
- 77
- FWCI
- 30.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.